Skip to main content

Table 1 Blood-gas-analysis and MAP: in both arms of the study (thrombin blockage with argatroban and PAR1-antagonism with SCH79797) two arterial blood samples were taken

From: Thrombin contributes to the injury development and neurological deficit after acute subdural hemorrhage in rats only in collaboration with additional blood-derived factors

Group

MAP (mmHg)

pH

pCO2 (mmHg)

pO2 (mmHg)

SHCO3 (mmol/l)

SBE (mmol/l)

Hb. (g/dl)

Hkt. (%)

Gluc. (mg/dl)

Lactate (mmol/l)

Argatroban: baseline calibration

Sham

65.1 ± 4.2

7.38 ± 0.02

46.1 ± 2.4

149.0 ± 8.9

261 ± 0.5

2.5 ± 0.6

14.3 ± 0.2

43.8 ± 0.7

242.8 ± 20.0

1.9 ± 0.2

Vehicle

66.3 ± 3.8

7.40 ± 0.02

45.4 ± 2.3

143.0 ± 7.7

26.9 ± 0.6

3.0 ± 0.6

14.1 ± 0.3

43.4 ± 0.8

243.4 ± 22.7

1.9 ± 0.3

Argatroban

63.5 ± 5.7

7.40 ± 0.02

40.5 ± 2.2

134.8 ± 9.3

25.5 ± 1.0

1.2 ± 1.2

14.0 ± 0.5

43.0 ± 1.6

261.3 ± 18.3

1.8 ± 0.3

Argatroban: end of procedure

Sham

68.3 ± 4.1

7.29 ± 0.02

48.9 ± 4.9

112.3 ± 7.3

23.0 ± 1.8

0.9 ± 2.4

13.1 ± 1.0

40.4 ± 3.1

212.7 ± 61.3

1.4 ± 0.3

Vehicle

69.0 ± 3.3

7.35 ± 0.06

41.6 ± 7.1

123.3 ± 2.6

21.6 ± 1.4

3.3 ± 16

13.0 ± 0.2

40.1 ± 1.6

224.0 ± 20.4

1.2 ± 0.3

Argatroban

70.1 ± 4.6

7.33 ± 0.3

48.0 ± 4.8

124.7 ± 9.8

23.5 ± 1.4

0.5 ± 1.7

13.8 ± 0.4

42.2 ± 1.1

293.8 ± 28.4

1.7 ± 0.4

SCH-79797: baseline calibration

Sham

85.0 ± 1.0

7.38 ± 0.02

42.0 ± 3.0

137.8 ± 8.7

25.2 ± 1.0

0.6 ± 1.1

13.8 ± 0.4

42.6 ± 1.3

296.3 ± 15.4

1.8 ± 0.2

Vehicle

77.7 ± 0.8

7.40 ± 0.02

43.4 ± 2.5

130.8 ± 11.2

26.9 ± 0.5

2.2 ± 0.8

13.5 ± 0.4

41.4 ± 1.2

258.4 ± 14.8

1.7 ± 0.4

SCH-1

76.9 ± 1.0

7.41 ± 0.01

37.7 ± 1.1

120.6 ± 8.1

25.1 ± 0.5

1.1 ± 0.5

12.3 ± 0.3

37.2 ± 1.1

306.8 ± 16.6

1.24 ± 0.16

SCH-5

79.9 ± 2.2

7.42 ± 0.01

39.0 ± 0.7

125.7 ± 7.9

26.5 ± 0.4

2.7 ± 0.6

12.8 ± 0.6

39.6 ± 2.0

301.2 ± 19.3

1.71 ± 0.3

SCH-79797: end of procedure

Sham

81.7 ± 1.8

7.414 ± 0.01

40.7 ± 109

129.7 ± 5.4

26.2 ± 0.6

2.0 ± 0.5

14.3 ± 0.3

43.8 ± 1.0

291.3 ± 12.7

1.6 ± 0.2

Vehicle

75.1 ± 1.5

7.4 ± 0.1

41.1 ± 1.4

147.8 ± 3.7

25.7 ± 0.7

1.6 ± 0.7

13.1 ± 0.5

40.5 ± 1.4

250.0 ± 8.0

1.3 ± 0.3

SCH-1

78.2 ± 1.9

7.42 ± 0.01

36.8 ± 0.6

130.2 ± 4.7

24.6 ± 0.5

1.4 ± 0.4

12.7 ± 0.2

37.2 ± 1.1

296.8 ± 15.6

14 ± 0.1

SCH-5

76.9 ± 2.0

7.41 ± 0.02

37.9 ± 1.3

123.0 ± 6.6

25.3 ± 0.5

1.8 ± 0.5

12.3 ± 0.4

37.6 ± 1.4

265.4 ± 13.6

1.5 ± 0.2

  1. One sample was taken during the CBF baseline measurement (− 10 to 0 min) and one at the end of the observational period (0–60 min after ASDH). All parameters were in a physiological range and did not differ between the groups. The MAP was monitored continuously. In the sixth minute after the start of the subdural infusion the MAP raised to a maximum in all ASDH groups. After that MAP dropped back within 30 min to baseline levels until the end of the observational period. Stable and physiological data in the blood-gas-analysis and comparable results in MAP suggest no differences between the groups due to anesthesia, ventilation or surgical procedures. All values mean ± SEM
Back to article page

BMC Neuroscience

ISSN: 1471-2202

Contact us